Dormosedan (Detomidine) Injection - 10mg/ml, 20 ml Vial

This medicine requires valid prescription.

Product Code : P0000001505

Sedative and Analgesic For Horses

Quantity :

LOCAL PHARMACY PICKUP

$0.00

Save up to 50%

Not Available For Local Pharmacy Pickup

HOME DELIVERY

$394.95

** Free Standard Shipping In All Home Delivery

Not Available For Home Delivery

LOCAL PHARMACY PICKUP

  1. Add the medication to your cart.
  2. Pay for your order.
  3. Take your printed or digital Pin Paws Rx voucher to your local pharmacy and present when picking up your medication.
  4. There will be no money owed at the pharmacy.
  5. A valid prescription will be required.

HOME DELIVERY

  1. Complete your profile information.
  2. Add the medication to your cart.
  3. Provide your Veterinarian and or pharmacy Details for prescription transfers.
  4. Our pharmacy team will obtain the prescription for the medicatin ordered and have it delivered to your home.


Dormosedan - Pfizer is indicated for use as a sedative and analgesic to facilitate minor surgical and diagnostic procedures in mature horses and yearlings. It has been used successfully for the following: to calm fractious horses, to provide relief from abdominal pain, to facilitate bronchoscopy, bronchoalveolar lavage, nasogastric intubation, nonreproductive rectal palpations, suturing of skin lacerations, and castrations. Additionally, an approved, local infiltration anesthetic is indicated for castration.

  • Provides non-narcotic sedation
  • Wide margin of safety
  • Predictable and effective sedation
  • Only a2 -agonist which has significant analgesia extending more than 15 minutes post administration.

Dosage and Administration:
For Sedation: Administer Dormosedan IV or IM at the rates of 20 or 40 mcg detomidine hydrochloride per kg of body weight (0.2 or 0.4 mL of Dormosedan per 100 kg or 220 lb), depending on the depth and duration of sedation required. Onset of sedative effects should be reached within 2-4 minutes after IV administration and 3-5 minutes after IM administration. Twenty mcg/kg will provide 30-90 minutes of sedation and 40 mcg/kg will provide approximately 90 minutes to 2 hours of sedation.

For Analgesia: Administer Dormosedan IV at the rates of 20 or 40 mcg detomidine hydrochloride per kg of body weight (0.2 or 0.4 mL of Dormosedanper 100 kg or 220 lb), depending on the depth and duration of analgesia required. Twenty mcg/kg will usually begin to take effect in 2-4 minutes and provide 30-45 minutes of analgesia. The 40 mcg/kg dose will also begin to take effect in 2-4 minutes and provide 45-75 minutes of analgesia.

For Both Sedation and Analgesia: Administer Dormosedan IV at the rates of 20 or 40 mcg detomidine hydrochloride per kg of body weight (0.2 or 0.4 mL of Dormosedan® per 100 kg or 220 lb), depending on the depth and duration of sedation and analgesia required.

Before and after injection, the animal should be allowed to rest quietly.

Contraindications:

Dormosedan should not be used in horses with pre-existing AV or SA block, with severe coronary insufficiency, cerebrovascular disease, respiratory disease, or chronic renal failure. Intravenous potentiated sulfonamides should not be used in anesthetized or sedated horses as potentially fatal dysrhythmias may occur.

Information on the possible effects of detomidine hydrochloride in breeding horses is limited to uncontrolled clinical reports; therefore, this drug is not recommended for use in breeding animals.


Dormosedan is not for use in horses intended for food.


Precautions:

Before administration, careful consideration should be given to administering Dormosedan to horses approaching or in endotoxic or traumatic shock, to horses with advanced liver or kidney disease, or to horses under stress from extreme heat, cold, fatigue, or high altitude. Protect treated horses from temperature extremes. Some horses, although apparently deeply sedated, may still respond to external stimuli. Routine safety measures should be employed to protect practitioners and handlers. Allowing the horse to stand quietly for 5 minutes before administration and for 10-15 minutes after injection may improve the response to Dormosedan.

Dormosedan is a potent a2-agonist, and extreme caution should be exercised in its use with other sedative or analgesic drugs for they may produce additive effects.

When using any analgesic to help alleviate abdominal pain, a complete physical examination and diagnostic work-up are necessary to determine the etiology of the pain.

Food and water should be withheld until the sedative effect of Dormosedan has worn off.


Occasional reports of anaphylactic-like reactions have been received, including 1 or more of the following: urticaria, skin plaques, dyspnea, edema of the upper airways, trembling, recumbency, and death. The use of epinephrine should be avoided since epinephrine may potentiate the effects of a2-agonists. Reports of mild adverse reactions have resolved uneventfully without treatment. Severe adverse reactions should be treated symptomatically. As with all a2-agonists, the potential for isolated cases of hypersensitivity exist, including paradoxical response (excitation).

Side Effects: 
Horses treated with Dormosedan exhibit hypertension. Bradycardia routinely occurs 1 minute after injection. The relationship between hypertension and bradycardia is consistent with an adaptive baroreceptor response to the increased pressure and inconsistent with a primary drug-induced bradycardia. Piloerection, sweating, salivation, and slight muscle tremors are frequently seen after administration. Partial transient penis prolapse may be seen. Partial AV and SA blocks may occur with decreased heart and respiratory rates. Urination typically occurs during recovery at about 45-60 minutes posttreatment, depending on dosage. Incoordination or staggering is usually seen only during the first 3-5 minutes after injection, until animals have secured a firm footing.

Because of continued lowering of the head during sedation, mucus discharges from the nose and, occasionally, edema of the head and face may be seen. Holding the head in a slightly elevated position generally prevents these effects.


Additional information not available for this medicine.